Anixa Biosciences Presents Breast Cancer Vaccine Phase 1 Data Showing All Major Endpoints Met

Bitget2026/10/29 23:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Anixa Biosciences completed its Phase 1 breast cancer vaccine trial, meeting all major endpoints; Phase 2 enrollment is the next milestone.
Among 35 patients dosed, 74% showed the protocol-specified immune response; no safety concerns were reported.
Combining the vaccine with Keytruda produced no additional adverse effects, supporting combination use.
Lira-cel remains in Phase 1 development for ovarian cancer, with periodic data releases tied to enrollment.
Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt; last fiscal year's cash burn was $7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anixa Biosciences Presents Breast Cancer Vaccine Phase 1 Data Showing All Major Endpoints Met

You may also like

Crypto prices